JP5448343B2 - 化粧品、特に毛髪のための複合栄養ベースの使用 - Google Patents
化粧品、特に毛髪のための複合栄養ベースの使用 Download PDFInfo
- Publication number
- JP5448343B2 JP5448343B2 JP2007547572A JP2007547572A JP5448343B2 JP 5448343 B2 JP5448343 B2 JP 5448343B2 JP 2007547572 A JP2007547572 A JP 2007547572A JP 2007547572 A JP2007547572 A JP 2007547572A JP 5448343 B2 JP5448343 B2 JP 5448343B2
- Authority
- JP
- Japan
- Prior art keywords
- base according
- hair
- base
- concentration
- scalp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004209 hair Anatomy 0.000 title claims description 33
- 239000002537 cosmetic Substances 0.000 title claims description 13
- 235000016709 nutrition Nutrition 0.000 title claims description 11
- 230000035764 nutrition Effects 0.000 title claims description 10
- 210000004761 scalp Anatomy 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 6
- 239000006143 cell culture medium Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000011573 trace mineral Substances 0.000 claims description 5
- 235000013619 trace mineral Nutrition 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 239000000061 acid fraction Substances 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 2
- 238000007659 chevron notched beam method Methods 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 37
- 210000002510 keratinocyte Anatomy 0.000 description 20
- 239000002775 capsule Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 17
- 229960003632 minoxidil Drugs 0.000 description 17
- 210000004919 hair shaft Anatomy 0.000 description 16
- 239000012634 fragment Substances 0.000 description 14
- 230000000394 mitotic effect Effects 0.000 description 14
- 201000004384 Alopecia Diseases 0.000 description 12
- 230000012010 growth Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000009786 epithelial differentiation Effects 0.000 description 7
- 238000002991 immunohistochemical analysis Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 231100000360 alopecia Toxicity 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- 230000003676 hair loss Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000003125 aqueous solvent Substances 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 210000004955 epithelial membrane Anatomy 0.000 description 2
- 230000008508 epithelial proliferation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- -1 zinc sulfate Chemical class 0.000 description 2
- PCLCDPVEEFVAAQ-UHFFFAOYSA-N BCA 1 Chemical compound CC(CO)CCCC(C)C1=CCC(C)(O)C1CC2=C(O)C(O)CCC2=O PCLCDPVEEFVAAQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CFMSAGJXJWTBNP-ZEOFCTJWSA-N [14C@@H]12C(CC[C@@]1(C)CC[C@H]1[C@H]2CCC2=CCCC[C@]12C)(O)O Chemical class [14C@@H]12C(CC[C@@]1(C)CC[C@H]1[C@H]2CCC2=CCCC[C@]12C)(O)O CFMSAGJXJWTBNP-ZEOFCTJWSA-N 0.000 description 1
- MUMGGOZAMZWBJJ-JGVWJMRDSA-N [14C@@H]12CC[C@H](O)[C@@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C Chemical compound [14C@@H]12CC[C@H](O)[C@@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C MUMGGOZAMZWBJJ-JGVWJMRDSA-N 0.000 description 1
- NVKAWKQGWWIWPM-BPBNVRBRSA-N [14C@@H]12CC[C@H](O)[C@@]1(C)CC[C@H]1[C@H]2CC[C@H]2CC(=O)CC[C@]12C Chemical compound [14C@@H]12CC[C@H](O)[C@@]1(C)CC[C@H]1[C@H]2CC[C@H]2CC(=O)CC[C@]12C NVKAWKQGWWIWPM-BPBNVRBRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- OQUUTERJWTYTHP-UHFFFAOYSA-N butanedioate;1h-tetrazol-1-ium Chemical compound [NH2+]1C=NN=N1.[NH2+]1C=NN=N1.[O-]C(=O)CCC([O-])=O OQUUTERJWTYTHP-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Description
−含硫アミノ酸の総重量濃度が104mg/L以下である;
−含硫アミノ酸を含むアミノ酸の総重量濃度が0.25と0.35%の間、例えば約0.326%に等しい;
−前記ビタミン画分の重量濃度が0.005と0.011%の間である;
−微量元素と金属塩を含む無機成分の重量濃度が1.25と1.35%の間、例えば1.347-1.348重量%に等しい;
−グルコース濃度が0.1%と0.6%の間、例えば0.45%と0.6%の間である;
−L-ヒドロキシプロリン濃度が0.003%と0.01%の間、例えば0.003%と0.01%の間である;
−アスコルビン酸組成が0.00001%と0.001%の間、例えば0.0001%と0.001%の間である;
−以下の化合物、すなわちアデノシン、グアニン、デオキシリボース、及びリボースの各濃度が0.000001%と0.0001%の間、例えば0.00001%と0.0001%の間である;
−美容的に活性のある量の少なくとも1つのタイプI 5α-リダクターゼ酵素インヒビターを含む;
−前記タイプI 5α-リダクターゼ酵素インヒビターが、亜鉛塩、例えば硫酸亜鉛、及び/またはビタミンB6を含む;
−前記複合栄養ベースは、総量が0と22.05mg/Lの間、好ましくは5と15mg/Lの間であるカルシウムを含む;
−前記複合栄養ベースは、0.01と1重量%の間の濃度で、例えばミルクから抽出されたペプチドを含む;
−当該水性相のpHが、7.4と7.5の間に調整されている;
−当該水性相の浸透圧が、高くても300と350μOsmの間に調整されている;
の少なくとも1つを含み、単独または組み合わせて考慮されて良い。
−D. Stamatiadis et al, “Inhibition of 5α-reductase activity, in human skin by zinc and azelaic acid”, British Journal of Dermatology(1988)119, 627-632(特にpp.628-629を参照)
を教えることによって特徴づけされ得、または特定され得る。
−用いられた物質は、1,2[3H]-テストステロン、[14C]-テストステロン、[14C]-ジヒドロテストステロン、[14C]-Δ4-アンドロステンジオン、[14C]-アンドロステンジオール、及びNADPH;
−当該5α-リダクターゼ酵素のin vitro供給源は、2から3ヶ月の年齢の子供の包皮を覆う皮膚のサンプルから構成される;
−この皮膚のホモジェネートを、次第に増加する濃度の[3H]-テストステロンとNADPH、及び阻害の候補生成物または物質の存在下でインキュベートし、 [14C]-ステロイドの添加後、代謝産物を分離し、テストステロンとΔ4-アンドロステンジオンの量を測定する。
pH 5.0-7.0
(水中に0.5%のMPC粉末)
乾燥度の減少(102℃で2時間) 2.0-6.0%
窒素(ケルダール) 1.4-1.9%
タンパク質(Sigma社製キットBCA-1) 11.0-16.0%
乳糖(Boehringer社製キット) 65.0-71.0%
乳酸(+)(Boehringer社製キット) 4.5-8.0%
灰(1000℃) 6.0-9.0%
残留脂肪 <0.5%
電気泳動(SDS-PAGE) 相当する
生物学的活性−50%有効濃度 50-500μg/mL
(移動テスト)
を有する。
−特に成人における雄性発生脱毛症の場合において、毛幹の間質におけるケラチン合成細胞の成長を増大し、それによって、毛髪の増加または再生を助け、毛髪の減少を安定化する;
−後発性の多毛症等の副作用または非所望の効果が事実上存在しない;
を提供する。
このテストは基準化合物としてのミノキシジルに関し、その後、本発明のCNBの有効性を比較するために前記基準化合物と比較する。
当該ケラチン合成細胞を、96ウェルマイクロプレートに、1ウェルにつき20,000細胞の割合で、200μLのKSFM標準培養培地(Invitrogen社)中にまいた。前記プレートを、6% CO2を含む湿気のある環境の中で37℃で24時間培養した。
試験される種々の濃度を、PBS中に5%含むミノキシジル(水溶性硫酸塩)のストック溶液を用いて調製した。試験された濃度範囲は、0.0001%から2%に及んだ。
前記KSFM培地の除去後、ミノキシジルの種々の希釈液を当該細胞に接触させた。当該実験の間、当該培地を取り替えなかった。各項目について4つ1組で実施した。当該細胞毒性(WST-1を用いたテスト)を、接触の24時間と48時間後に測定した。
当該吸光度を、ELISAマイクロプレートリーダーを用いて450nmで読み取った。
このテストの目的は、その組成物が表2に記載されているところの当該CNBの中に、低濃度でまかれた正常なヒトケラチン合成細胞の増殖を測定することであった。
当該ケラチン合成細胞を96ウェルプレートに低濃度で標準KSFM培地中にまき、この培地中にまいた後24時間増殖させた。
−KSFM;
−MPC複合体なしの表2に係るCNB;
−MPCを0.2mg/mLで含む表2に係るCNB;
中に放置した。
・0.2mg/mLの濃度でMPC複合体の存在下で、表2に係るCNBに関して、当該ケラチン合成細胞の持続的細胞増殖が観察された;
・MPC複合体の添加なしで、表2に係るCNBに関して(低カルシウム条件において)、細胞の増殖は観察されなかった。
当該目的は、生存中に維持された頭皮断片の増殖と分化への、表1に係るCNBの有効性を測定することであった。
異なる5人のドナー(雄性発生脱毛症に罹患している患者、毛髪が保持されている領域と脱毛領域の間の接合部でサンプル採取した)からの頭皮断片を、培養ウェル上に位置するインサート中に堆積させた。
前記頭皮断片を、ブアン液で固定し、パラフィンで固定した。
上皮の増殖を、抗Ki67抗体(細胞サイクルのM、S、G1、及びG2期における細胞の標識をする)を用いた免疫組織化学によって分析した。免疫検出を、3層の間接的免疫ペルオキシダーゼ技術を用いて実施し、増幅させ(DAKOキット)、DABで発色させた。
上皮性分化を、全抗サイトケラチン抗体(Novocastra社)で特定した。
−マイナス :スコア0-
−僅か :スコア1
−中程度 :スコア2
−高い :スコア3
−非常に高い:スコア4
を用いて評価した。
減らした偏差についてのスチューデント検定、または対のサンプル検定によって統計的解析を実施した。有意の閾値を5%に設定した。
有糸分裂活性についての分析を、以下の表Iに示す。
上皮性分化についての分析を、以下の表IIに示す。
細胞増殖(前記抗Ki67抗体を用いた免疫組織化学):表面表皮と嚢の外側上皮被膜の標識された細胞のパーセンテージ
このテストは、生存を維持された頭皮断片を用いた、毛根の刺激(細胞増殖)への、表2に係るCNBの有効性を試験することを意図した。
異なる6人のドナー(非脱毛症患者の頚顔面リフト)からの頭皮断片を、培養ウェル上に位置するインサート中に堆積させた。
前記頭皮断片を、ブアン液で固定し、パラフィンで固定した。
減らした偏差についてのスチューデント検定、または対のサンプル検定によって統計的解析を実施した。有意の閾値を5%に設定した。
有糸分裂活性についての分析を、以下の表Iに示す。
有糸分裂活性についての分析を、以下の表IIに示す。
細胞増殖(前記抗Ki67抗体を用いた免疫組織化学):毛嚢の根元における標識された間質細胞のパーセンテージ
#:表2に係るCNBとミノキシジル0.01%の間の比較:統計的な有意差(片側対スチューデント検定、p<0.05)
細胞増殖(前記抗Ki67抗体を用いた免疫組織化学):嚢の外側上皮被膜における標識された細胞のパーセンテージ
#:表2に係るCNBとミノキシジル0.01%の間の比較:統計的な有意差(片側対スチューデント検定、p<0.05)
#:ミノキシジル0.01%とミノキシジル2%の間の比較:統計的な有意差(片側対スチューデント検定、p<0.05)
Claims (14)
- 水中の複合栄養ベースであって、不確定の組成を有するいずれかの追跡されない細胞成長因子、及び/または動物若しくは細胞由来のいずれかの生物学的抽出物を排除するという点において細胞培養培地とは区別され、前記ベースは、前記水に加えて、アミノ酸画分を0.25 %以上0.5 %未満、水溶性ビタミン画分を0.005 %以上0.2 %未満、及び微量元素と金属塩を含む無機画分を1.25 重量%以上5重量%未満からなり、前記ベースは、104mg/L以下の総重量濃度の含硫アミノ酸を含み、且つミルクから抽出されたペプチドを0.01と1重量%の間の濃度で含むことを特徴とする複合栄養ベース。
- 含硫アミノ酸を含むアミノ酸の総重量濃度が0.25と0.35%の間であることを特徴とする、請求項1に記載のベース。
- 前記ビタミン画分の重量濃度が0.005と0.015%の間であることを特徴とする、請求項1に記載のベース。
- 微量元素と金属塩を含む無機成分の重量濃度が1.25と1.35%の間であることを特徴とする、請求項1に記載のベース。
- グルコース濃度が0.1%と0.6%の間であることを特徴とする、請求項1に記載のベース。
- L-ヒドロキシプロリン濃度が0.003%と0.01%の間であることを特徴とする、請求項1に記載のベース。
- アスコルビン酸組成が0.00001%と0.001%の間であることを特徴とする、請求項1に記載のベース。
- 以下の化合物、すなわちアデノシン、グアニン、デオキシリボース、及びリボースの各濃度が0.000001%と0.0001%の間であることを特徴とする、請求項1に記載のベース。
- 少なくとも1つのタイプI 5α-リダクターゼ酵素インヒビターを含むことを特徴とする、請求項1に記載のベース。
- 総量が0と22.05mg/Lの間であるカルシウムを含むことを特徴とする、請求項1に記載のベース。
- 前記水性相のpHが、7.4と7.5の間に調整されていることを特徴とする、請求項1に記載のベース。
- 前記水性相の浸透圧が、高くても300と350μOsmの間に調整されていることを特徴とする、請求項1に記載のベース。
- 局所的使用のための、特に男性における毛髪及び/または頭皮の処理のための化粧品組成物であって、請求項1から12のいずれか一項に記載の複合栄養ベースと美容的に許容し得る支持体を含む化粧品組成物。
- 男性または女性における毛髪及び/または頭皮を処理するための方法であって、請求項1から12のいずれか一項に記載の複合栄養ベース、または請求項13に記載の化粧品組成物を頭皮表面へ局所的に適用することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0413658 | 2004-12-21 | ||
FR0413658A FR2879443B1 (fr) | 2004-12-21 | 2004-12-21 | Utilisation d'une base nutritive complexe dans le domaine cosmetique, en particulier capillaire |
PCT/FR2005/003228 WO2006067335A1 (fr) | 2004-12-21 | 2005-12-21 | Utilisation d'une base nutritive complexe dans le domaine cosmetique, en particulier capillaire |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008524314A JP2008524314A (ja) | 2008-07-10 |
JP5448343B2 true JP5448343B2 (ja) | 2014-03-19 |
Family
ID=34952916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007547572A Active JP5448343B2 (ja) | 2004-12-21 | 2005-12-21 | 化粧品、特に毛髪のための複合栄養ベースの使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7820148B2 (ja) |
EP (1) | EP1827365B1 (ja) |
JP (1) | JP5448343B2 (ja) |
KR (1) | KR101291489B1 (ja) |
CN (1) | CN101098674B (ja) |
CA (1) | CA2593923C (ja) |
ES (1) | ES2642038T3 (ja) |
FR (1) | FR2879443B1 (ja) |
HK (1) | HK1116668A1 (ja) |
WO (1) | WO2006067335A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008001640A1 (es) * | 2007-06-08 | 2008-11-07 | Bergen Teknologioverforing As | Uso de hidroxiprolina para preparar una composicion de alemento destinada a promover el crecimiento de un animal, como peces, aves y mamiferos. |
FR2948286B1 (fr) * | 2009-07-27 | 2011-08-26 | Jean-Noel Thorel | Composition injectable associant un agent de comblement et un milieu de croissance des fibroblastes |
KR100977672B1 (ko) * | 2009-12-31 | 2010-08-24 | 주식회사 코리아나화장품 | 생체 모방 영양 복합물을 유효 성분으로 포함하는 피부 노화 방지용 화장료 조성물 |
FI3900699T3 (fi) * | 2015-11-25 | 2023-09-25 | JeNaCell GmbH | Bioteknologisesti valmistettua selluloosaa sisältävä tuote dermatologiseen käyttöön |
GB201703656D0 (en) * | 2017-03-07 | 2017-04-19 | Univ Sheffield | Wound healing medicament |
US11147761B2 (en) * | 2018-01-12 | 2021-10-19 | Nicole Akmenkalns | Topical supplement composition and method of use |
CN112245312A (zh) * | 2020-10-23 | 2021-01-22 | 介一生物工程技术(大连)有限公司 | 一种防脱发组合物及其应用 |
KR102394488B1 (ko) * | 2021-11-25 | 2022-05-04 | (주)헤세드바이오 | 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7639M (ja) * | 1967-09-14 | 1970-02-02 | ||
EP0107885B1 (en) | 1982-10-29 | 1987-07-29 | Crinos Industria Farmacobiologica S.p.A. | Cosmetic preparations promoting the trophism of the skin and of the related hair follicles |
US5182269A (en) * | 1987-09-23 | 1993-01-26 | Crinos Industria Farmacobiologica Spa | Composition for topical use having hair stimulating, anti-dandruff and anti-seborrhoic activity |
CA2009204A1 (en) * | 1989-02-06 | 1990-08-06 | Andries J. C. Strydom | Medicament |
US5739033A (en) * | 1989-09-20 | 1998-04-14 | Vivorx, Inc. | Physiological cell separation and method of separating cells using same |
JPH05271040A (ja) * | 1991-11-27 | 1993-10-19 | Seiwa Kasei:Kk | 染毛剤 |
GB9210756D0 (en) * | 1992-05-20 | 1992-07-08 | Unilever Plc | Cosmetic composition |
FR2694692B1 (fr) * | 1992-08-13 | 1994-10-28 | Thorel Jean Noel | Préparation cosmétique de nutrition de la peau. |
JP3080797B2 (ja) * | 1992-12-01 | 2000-08-28 | ポーラ化成工業株式会社 | ペプチドを含有する化粧料 |
US5597575A (en) * | 1994-06-06 | 1997-01-28 | Breitbarth; Richard | Composition for stimulating and inducing hair growth |
IT1271342B (it) * | 1994-12-28 | 1997-05-27 | Indena Spa | Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le contengono |
DE69611230T2 (de) * | 1995-01-09 | 2001-04-05 | Thorel Jean Noel | Nährstoff für epidermale zellkultur und verwendung |
JPH09275997A (ja) * | 1996-04-18 | 1997-10-28 | Morinaga Milk Ind Co Ltd | メラニン産生抑制物質の評価方法とメラニン産生抑制 剤 |
US6146664A (en) * | 1998-07-10 | 2000-11-14 | Shaklee Corporation | Stable topical ascorbic acid compositions |
CA2296311A1 (en) * | 1999-01-28 | 2000-07-28 | Universite Laval | Enzymatic hydrolysate of milk proteins |
ITMI20011019A1 (it) * | 2001-05-17 | 2002-11-17 | Carlo Ghisalberti | Sostanze furiliche per uso topico |
EP1262166A1 (de) * | 2001-06-01 | 2002-12-04 | Cognis France S.A. | Kosmetische und/oder pharmazeutische Zubereitungen enthaltend einen Extrakt aus Pterocarpus marsupium |
EP1785130A3 (en) * | 2001-07-18 | 2007-11-28 | Unilever PLC | Hair and/or scalp treatment compositions |
FR2864445B1 (fr) * | 2003-12-30 | 2006-04-28 | Jean Noel Thorel | Utilisation topique d'une base nutritive complexe |
-
2004
- 2004-12-21 FR FR0413658A patent/FR2879443B1/fr active Active
-
2005
- 2005-12-21 CN CN2005800463233A patent/CN101098674B/zh active Active
- 2005-12-21 WO PCT/FR2005/003228 patent/WO2006067335A1/fr active Application Filing
- 2005-12-21 ES ES05850571.0T patent/ES2642038T3/es active Active
- 2005-12-21 JP JP2007547572A patent/JP5448343B2/ja active Active
- 2005-12-21 KR KR1020077015746A patent/KR101291489B1/ko active IP Right Grant
- 2005-12-21 EP EP05850571.0A patent/EP1827365B1/fr active Active
- 2005-12-21 CA CA2593923A patent/CA2593923C/fr active Active
-
2007
- 2007-06-20 US US11/820,750 patent/US7820148B2/en active Active
-
2008
- 2008-06-25 HK HK08107059.5A patent/HK1116668A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1827365A1 (fr) | 2007-09-05 |
WO2006067335B1 (fr) | 2006-11-09 |
ES2642038T3 (es) | 2017-11-15 |
JP2008524314A (ja) | 2008-07-10 |
US7820148B2 (en) | 2010-10-26 |
US20070248559A1 (en) | 2007-10-25 |
FR2879443B1 (fr) | 2007-07-13 |
CA2593923A1 (fr) | 2006-06-29 |
HK1116668A1 (en) | 2009-01-02 |
EP1827365B1 (fr) | 2017-09-20 |
FR2879443A1 (fr) | 2006-06-23 |
CA2593923C (fr) | 2013-07-16 |
CN101098674A (zh) | 2008-01-02 |
KR20070091647A (ko) | 2007-09-11 |
KR101291489B1 (ko) | 2013-07-30 |
CN101098674B (zh) | 2012-05-09 |
WO2006067335A1 (fr) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5448343B2 (ja) | 化粧品、特に毛髪のための複合栄養ベースの使用 | |
JP5044071B2 (ja) | 真皮表皮接合部中のコラーゲンiv量を増加させる為の化粧剤としての化粧学上許容されるサポニン又はサポゲノールの少なくとも1種の使用 | |
JP2004505007A (ja) | 抗グリケーション剤としての少なくとも1つのスノキ属植物の抽出物の使用 | |
CN104507455B (zh) | 用于干性皮肤的化合物以及抗衰老应用 | |
JP4117773B2 (ja) | N−アシルアミノアミドファミリーのエラスターゼ阻害剤と少なくとも1種の抗真菌剤又は少なくとも1種の抗菌剤の組み合わせを含む化粧品用又は皮膚用組成物 | |
KR101662603B1 (ko) | 모유두세포 및 모모세포의 활성화능을 갖는 펩톤발효물을 포함하는 탈모방지 또는 발모촉진용 화장료 조성물, 및 이의 제형 | |
FR2755367A1 (fr) | Utilisation d'un extrait de potentille erecta dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
KR100614903B1 (ko) | 케라티노사이트 및/또는 섬유아세포를 함유하는 화장용조성물 | |
EP2561858A2 (en) | A composition for activating hair follicle stem cells to stimulate hair growth | |
JP2018536646A (ja) | 脱毛を防ぐ製剤 | |
KR101779480B1 (ko) | 펩톤발효물을 포함하는 탈모의 예방, 치료, 또는 발모촉진용 조성물, 및 이의 제형 | |
JP2023516927A (ja) | ヘチマ根抽出物を含む組成物 | |
JPH05124930A (ja) | 化粧料 | |
CN112137911A (zh) | 含有n-酰基二肽衍生物和乙醇酸的局部用组合物 | |
JP2004523488A (ja) | 皮膚の化粧的治療方法 | |
US20220331387A1 (en) | Extract of silybum marianum (l.) gaertn. akenes for promoting hair growth | |
US20200108126A1 (en) | Formulation and method for promoting hair growth | |
KR102613913B1 (ko) | 트리코데르마 아트로비리데 배양 추출물을 포함하는 탈모 예방 또는 발모 개선용 조성물 | |
JPH0665043A (ja) | 皮膚外用剤 | |
FR2764504A1 (fr) | Utilisation d'un derive delipide de lait en tant qu'agent destine a freiner la chute des cheveux et/ou induire et stimuler leur croissance | |
JP2003519663A (ja) | ディクトヨタル(Dictyotal)抽出物の局所薬組成物の製造での使用 | |
FR2767690A1 (fr) | Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
KR100918475B1 (ko) | 퍼옥시좀 증식활성화 수용체 델타에 특이적인 리간드를 포함하는 피부 외용제 조성물 | |
KR100461761B1 (ko) | 파네솔을 함유하는 피부 외용제 조성물 및 피부 건조증상 개선제 | |
FR3127219A1 (fr) | Nouveaux peptides et compositions pharmaceutiques et cosmetiques les contenants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130521 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131224 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5448343 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |